middle.news
Nexalis Therapeutics Advances Multiple Clinical Trials Amid Strategic Rebrand and Capital Raise
3:24pm on Thursday 30th of April, 2026 AEST
•
Healthcare
Read Story
Nexalis Therapeutics Advances Multiple Clinical Trials Amid Strategic Rebrand and Capital Raise
3:24pm on Thursday 30th of April, 2026 AEST
Key Points
Phase 1 trial dosing commenced for IRX-616a targeting panic disorder
IRX-211 Phase 2 program advancing with multiple clinical sites preparing
SRX-25 oral treatment protocol finalised for treatment-resistant depression
Company rebranded as Nexalis Therapeutics reflecting pipeline diversification
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nexalis Therapeutics (ASX:NX1)
OPEN ARTICLE